QwikCheck: Cutting Edge Technology for Small Retailers

QwikCheck: Cutting Edge Technology for Small Retailers

Hien Ta, CEO, QwikCheckHien Ta, CEO
“Whoever said money can't buy happiness,
simply didn't know where to go shopping.”—
Gertrude Stein, American author.

Most consumers, however, dread the pain of finding the right store or standing in long checkout lines while buying a product. In an era dominated by Amazon and, now, Amazon Go that deliver great customer experiences, single store retailers and chain operators need a technology partner who can deliver them the right technology that puts them at par with the technology giants and industry leaders. Small retailers who often incur cost by taking more labor on board to expedite the checkout process seldom give importance to the need to understand customers and their personalized requirements. QwikCheck can help them overcome their traditional limitations and lead the market. A retail solutions provider leveraging artificial intelligence and advanced analytics, QwikCheck allows small retailers to take a data-driven approach to understand customer’s shopping habits, maintain the right inventory, expedite the checkout process, and enhance upsell and cross-sell opportunities, all while delivering improved customer experiences. “QwikCheck uses customer information to provide predictive analysis regarding their shopping patterns and accelerate in-store sales,” says Hien Ta, CEO at QwikCheck.

The QwikCheck solutions are available on three platforms— EMV in-store kiosk, checkout mobile app and marketplace website. The kiosk and the mobile app help customers to checkout by themselves by just scanning the product and paying through their mobile phone, eliminating the need to stand in long lines. QwikCheck website, referred to as the 'marketplace', is a solution where a customer can search for a particular product and the store where it is available, saving time and effort. The three platforms provide users’ data to the operator to ensure a personalized and secure shopping experience.

QwikCheck aims to help retailers gain traction at par with an e-commerce website, breathing a new lease of life into brick-and-mortar stores

The kiosk and the app benefit the store by increasing the labor efficiency and allowing the checkout staff to do more than just billing, improving customer service. The kiosk can be integrated with the internal billing and inventory management systems in the store, while it can be physically customized based on the space available at the store, without having to change the existing infrastructure.

The cloud-based solution allows the three platforms to be mutualized and run on the EMV in-store kiosk that supports self-checkout through an intuitive interface. In parallel, the QwikCheck store website promotes a store's online presence by providing customers with the items available in the store and location, resulting in higher footfall. The analytics makes it possible to personalize the suggestions based on customer insights such as shopping habits, choices, and preferences, while aligning with compliance regulations to protect customer data privacy laws and other regulatory standards.

The benefits offered by QwikCheck to brick-and-mortar stores can be exemplified through the services provided to a retailer, whose store housed QwikCheck kiosk solution. The client, a smaller brick-and-mortar store, saw immense convenience and growth in the customer service. The client who was also the storeowner and the operator experienced a drop in operational costs and complexities owing to the self-checkout option, which changed the store operations for the better.

With nearly two decades of experience in PoS, payments, and fintech, Ta hints at integrating the self-checkout kiosk with an identity check-in solution that serves to increase the fill rate while decreasing the time spent on approving orders manually. Additionally, the company aims to use in-store cameras to augment shopping experience and security. With these services, “QwikCheck aims to help retailers gain traction at par with an e-commerce website, breathing a new lease of life into brick-and-mortar stores,” Ta extols.

QwikCheck News

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Ingelheim, Germany and Nantes, France – June 17, 2019, 6:00 p.m. CET - Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor.

“We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes for patients with difficult-to-treat cancers,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim.

“We are excited to begin first-in-human testing with this novel SIRPα-targeting compound, which we believe has first-in-class potential in the treatment of solid tumors,” said Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics. “This marks one of many anticipated milestones in the collaboration agreement with our partner Boehringer Ingelheim, and we look forward to advancing rapidly this potentially transformative treatment through the clinic. Milestones such as this one for the novel compounds our R&D teams develop have provided OSE with a stable financial base to grow steadily our first-in-class immuno-oncology pipeline.”

The study is conducted by OSE Immunotherapeutics as part of a collaboration and license agreement under which Boehringer Ingelheim obtained exclusive rights to BI 765063. Under the terms of the collaboration and license agreement, the clinical trial authorization obtained in March 2019 and dosing of the first patient in this Phase 1 trial triggers milestone payments of a total of €15 million to OSE Immunotherapeutics from Boehringer Ingelheim. This trial aims to characterize safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the immunotherapy in patients with advanced solid tumours.

ABOUT BI 765063 (formerly OSE-172)

BI 765063 is a monoclonal antibody antagonist of the key myeloid cell checkpoint inhibitor SIRPα. BI 765063 prevents the SIRPα ligand CD47, from binding to SIRPα thereby preventing cellular signalling that can reduce the anti-tumorigenic properties of myeloid cells such as macrophages and dendritic cells. In March 2019, OSE Immunotherapeutics received Clinical Trial Authorization for a Phase 1 study by two health agencies (France and Belgium) to evaluate BI 765063 in patients with advanced solid tumors. The study is conducted by OSE Immunotherapeutics as part of a collaboration and license agreement under which Boehringer Ingelheim obtained exclusive rights to BI 765063, originally signed in April 2018.